This is a multicenter, phase I randomized double-blind placebo controlled study to determine the safety, pharmacokinetics and pharmacodynamics of recombinant human D Nase 1 (rhDNase) in patients with systemic lupus erythematosus (SLE). The safety & tolerance of a single intravenous (IV) administration of rhDNase & multiple subcutaneous (SC) and IV doses of rhDNase will be determined. The pharmacokinetics of rhDNase after IV and SC administration will be characterized in patiens with SLE.
Showing the most recent 10 out of 859 publications